Year in Review: Updates in DLBCL Treatment

home / publications / supplements / year-in-review-updates-in-dlbcl-treatment
Sequencing Challenges Arise Amid New Approvals in DLBCL Paradigm

Sequencing Challenges Arise Amid New Approvals in DLBCL Paradigm

Jessica Hergert
October 5th 2020
Article

Andrew M. Evens, DO, MSc, discusses the approval of 3 new regimens and how they have reformed the treatment paradigm of relapsed/refractory diffuse-large B-cell lymphoma.

Selinexor May Offer Post–CAR T Potential in Relapsed/Refractory DLBCL

Selinexor May Offer Post–CAR T Potential in Relapsed/Refractory DLBCL

Brittany Cote
September 30th 2020
Article

Kami Maddocks, MD, discusses the significance of the selinexor approval in the diffuse large B-cell lymphoma treatment paradigm, emerging strategies that seek to address unmet needs, and remaining sequencing questions.

Dr. Pagel on Determining Treatment Based on Genetic Risk in Double- and Triple-Hit Lymphoma

Dr. Pagel on Determining Treatment Based on Genetic Risk in Double- and Triple-Hit Lymphoma

John M. Pagel, MD, PhD
September 29th 2020
Video

John M. Pagel, MD, PhD, discusses the utility of rituximab with etoposide, doxorubicin, cyclophosphamide, vincristine, and prednisone in double- and triple-hit lymphoma.

Dr. Maddocks on Ongoing Sequencing Challenges in DLBCL

Dr. Maddocks on Ongoing Sequencing Challenges in DLBCL

Kami J. Maddocks, MD
September 23rd 2020
Video

Kami J. Maddocks, MD, discusses ongoing sequencing challenges in diffuse large B-cell lymphoma.

Dr. Balzarotti on the Challenges of Treating Elderly DLBCL

Dr. Balzarotti on the Challenges of Treating Elderly DLBCL

Monica Balzarotti, MD
September 18th 2020
Video

Monica Balzarotti, MD, discusses the challenges of treating elderly patients with diffuse large B-cell lymphoma.

Dr. Pagel on the Evolution of Treatment in DLBCL

Dr. Pagel on the Evolution of Treatment in DLBCL

John M. Pagel, MD, PhD
September 16th 2020
Video

John M. Pagel, MD, PhD, discusses the evolution of treatment in diffuse large B-cell lymphoma.

Balzarotti Breaks Down New Developments in the Expanding DLBCL Paradigm

Balzarotti Breaks Down New Developments in the Expanding DLBCL Paradigm

Erica DiNapoli
September 9th 2020
Article

Monica Balzarotti, MD, discusses the current treatment landscape of DLBCL, including the recent FDA approval of selinexor for the treatment of adult patients with relapsed/refractory disease.

Brody Calls for Effective Predictive Biomarker of Response to Selinexor in DLBCL

Brody Calls for Effective Predictive Biomarker of Response to Selinexor in DLBCL

Erica DiNapoli
September 7th 2020
Article

Joshua Brody, MD, discusses recent developments in DLBCL treatment, the role of selinexor, and the need for effective biomarkers of response in the space.

Dr. Hill on the Challenges of Managing Heavily Pretreated DLBCL

Dr. Hill on the Challenges of Managing Heavily Pretreated DLBCL

Brian T. Hill, MD, PhD
September 2nd 2020
Video

Brian T. Hill, MD, PhD, discusses the challenges of managing heavily pretreated patients with diffuse large B-cell lymphoma.

Hill Highlights the Potential of Selinexor as a Less Intensive Option for DLBCL

Hill Highlights the Potential of Selinexor as a Less Intensive Option for DLBCL

Brittany Cote
August 31st 2020
Article

Brian T. Hill, MD, PhD, sheds light on XPO1 as a target in diffuse large B-cell lymphoma, the emergence of selinexor in the treatment landscape, and exciting agents in the pipeline.

Dr. Pagel on Challenges With ASCT in Relapsed/Refractory DLBCL

Dr. Pagel on Challenges With ASCT in Relapsed/Refractory DLBCL

John M. Pagel, MD, PhD
August 18th 2020
Video

John M. Pagel, MD, PhD, discusses challenges with autologous stem cell transplant in relapsed/refractory diffuse large B-cell lymphoma.

Dr. Pagel on the Importance of Screening for Double- and Triple-Hit DLBCL

Dr. Pagel on the Importance of Screening for Double- and Triple-Hit DLBCL

John M. Pagel, MD, PhD
August 13th 2020
Video

John M. Pagel, MD, PhD, discusses the importance of screening patients for double-hit and triple-hit diffuse large B-cell lymphoma.

FDA Approvals Augment Advances Made in the DLBCL Armamentarium

FDA Approvals Augment Advances Made in the DLBCL Armamentarium

Caroline Seymour
August 11th 2020
Article

John M. Pagel, MD, PhD, discusses current treatment approaches in frontline and relapsed/refractory DLBCL and provides insight on some of the agents that are generating excitement in the relapsed/refractory setting.